Clinical trials: Stage IIIB Lung Cancer
EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma
ETOP 15-19 ABC-lung is an international, multi-centre open-label, randomized phase II trial with two non-comparative parallel arms of atezolizumab plus bevacizumab with carboplatin-paclitaxel (Arm A) or atezolizumab, bevacizumab…
- Trial name
- ABC-lung (NCT04245085)
- Testing
- Atezolizumab, Bevacizumab, Carboplatin
- Where
- 18 sites in Germany, Singapore and 3 more
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- ETOP IBCSG Partners Foundation
Small Cell Lung Carcinoma Extensive Disease
Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer
This is a Phase IIIb, interventional, single arm, multicentre study to evaluate safety, effectivenees, use of resources and patient reporting outcomes in patients with ES-SCLC treated with durvalumab in combination with…
- Trial name
- CANTABRICO (NCT04712903)
- Testing
- Durvalumab, Cisplatin, Etoposide
- Where
- 34 sites in Spain
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- AstraZeneca